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Background-—Dilated cardiomyopathy is characterized by impaired contractility of cardiomyocytes, ventricular chamber dilatation,
and systolic dysfunction. Although mutations in genes expressed in the cardiomyocyte are the best described causes of reduced
contractility, the importance of endothelial-cardiomyocyte communication for proper cardiac function is increasingly appreciated.
In the present study, we investigate the role of the endothelial adhesion molecule platelet endothelial cell adhesion molecule
(PECAM-1) in the regulation of cardiac function.
Methods and Results-—Using cell culture and animal models, we show that PECAM-1 expressed in endothelial cells (ECs)
regulates cardiomyocyte contractility and cardiac function via the neuregulin-ErbB signaling pathway. Conscious echocardiography
revealed left ventricular (LV) chamber dilation and systolic dysfunction in PECAM-1/ mice in the absence of histological
abnormalities or defects in cardiac capillary density. Despite deficits in global cardiac function, cardiomyocytes isolated from
PECAM-1/ hearts displayed normal baseline and isoproterenol-stimulated contractility. Mechanistically, absence of PECAM-1
resulted in elevated NO/ROS signaling and NRG-1 release from ECs, which resulted in augmented phosphorylation of its receptor
ErbB2. Treatment of cardiomyocytes with conditioned media from PECAM-1/ ECs resulted in enhanced ErbB2 activation, which
was normalized by pre-treatment with an NRG-1 blocking antibody. To determine whether normalization of increased NRG-1 levels
could correct cardiac function, PECAM-1/ mice were treated with the NRG-1 blocking antibody. Echocardiography showed that
treatment significantly improved cardiac function of PECAM-1/ mice, as revealed by increased ejection fraction and fractional
shortening.
Conclusions-—We identify a novel role for PECAM-1 in regulating cardiac function via a paracrine NRG1-ErbB pathway. These data
highlight the importance of tightly regulated cellular communication for proper cardiac function. ( J Am Heart Assoc. 2015;4:
e001210 doi: 10.1161/JAHA.114.001210)
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E ndothelial cells (ECs) are in close physical proximity tocardiomyocytes in the heart, such that each cardiomyo-
cyte is surrounded by a dense network of capillary vessels
comprised of ECs. The endothelium releases factors such as
neuregulin (NRG-1) and nitric oxide (NO), which can affect
numerous parameters of cardiomyocyte function, including
their contractility.1 Cardiomyocytes, in turn, secrete factors
that can also direct EC function.2 Recent data provide a
compelling link between EC dysfunction and the progression
of dilated cardiomyopathy (DCM), a condition characterized
by dilatation and impaired contraction of the heart that can
lead to heart failure and sudden death.3 Although critical for
understanding the physiological and pathological processes of
the heart, our knowledge of the pathways that regulate EC-
cardiomyocyte crosstalk is limited. Importantly, we know that
impaired release and/or activity of the molecules implicated
in crosstalk can result in heart failure. For example, the
knockout mouse of apelin, a protein released by ECs and
important for a number of physiological functions, develops
impaired contractility with age.4–6 The NRG-1-ErbB signaling
pathway represents another pertinent example. Interest in
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this pathway was generated following the observation that
women treated with trastuzumab, a monoclonal antibody
against the NRG-1 receptor ErbB2 (or HER2), have increased
risk for development of heart failure.7 Numerous studies have
supported a role for NRG-1 and ErbB2 in heart failure; the
ventricular-specific knockout of ErbB2 develops DCM with
age8 and treatment with NRG-1 improves cardiac function in
models of cardiomyopathy.9 Finally, studies have suggested a
role for hemodynamic stress, hypoxia as well as mechanical
stress in the development of DCM.10
Platelet endothelial cell adhesion molecule-1 (PECAM-1) is
a cell adhesion and signaling molecule expressed in blood and
vascular cells that has roles in regulation of endothelial
junctional integrity; transendothelial migration; as well as
angiogenesis.11 Our own work has shown that PECAM-1
functions as a mechanosensor in ECs and confers the ability
to sense and respond to the hemodynamic force of flowing
blood,12 as well as tensional force using a magnetic tweezers
system.13 Although PECAM-1 initiates mechanosignaling
specifically in ECs, its presence (or absence) can have
profound consequences on EC communication with other cell
types, including vascular smooth muscle cells (VSMCs), and
thus affect the physiology and pathology of the vessel as a
whole. The PECAM-1/ mouse is viable, but displays
vascular defects in response to changes in hemodynamic
forces. Specifically, PECAM-1/ mice display blunted flow-
mediated dilation due to misregulated NO production14 and
reduced VSMC relaxation.15,16 In addition, our lab has shown
that PECAM-1 deficiency results in impaired flow-mediated
vascular remodeling that results in reduced VSMC activation
and signaling.17,18
As EC-cardiomyocyte crosstalk is important in regulating
cardiac function and cellular communication in the vessel wall
is perturbed in the absence of PECAM-1, we hypothesized that
cardiac function is impaired in PECAM-1/ mice. Here, using
a combination of knockout mouse models and cell culture
systems, we show that increased NRG-1 release in PECAM-1
knockout ECs results in augmented ErbB2 phosphorylation in
cardiomyocytes and impaired cardiac function, at least in part
through effects on cardiomyocyte contractility. This novel
PECAM-1/NRG-1/ErbB2 pathway may represent a fundamen-
tal mechanism that coordinates endothelial and cardiomyo-
cyte signaling in the heart.
Materials and Methods
Animals
PECAM-1/ C57BL/6 mice were kindly provided by Dr P.
Newman (Blood Research Institute, Blood Center of Wiscon-
sin, Milwaukee), bred in house and used in accordance with
the guidelines of the National Institute of Health and for the
care and use of laboratory animals (approved by the
Institutional Animal Care and Use Committees of the Univer-
sity of North Carolina at Chapel Hill). Male PECAM-1/ and
age-matched wild-type PECAM-1+/+ littermates were used for
all studies.
Cell Culture
PECAM-1-knockout (PE-KO) cells and cells reconstituted with
murine full-length PECAM-1 (PE-RC) were prepared as previ-
ously described.14,19 The murine HL-1 cell line was a gift from
Dr W.C. Claycomb (Louisiana State University Medical Centre,
New Orleans, LA) and maintained as described.20
Cardiac Function and Hemodynamic
Measurements
Conscious echocardiography was performed as previously
described using a Vevo 2100 ultrasound biomicroscopy
system.21,22 LV dimension data represent the average of at
least 3 independent waveforms. Blood pressure measure-
ments were performed in conscious animals.23 In vivo left
ventricular function was assessed by PV catheter using a 1.2
French catheter-tip pressure transducer (Scisense, Inc, Lon-
don, Ontario, Canada). The mouse was anesthetized with 2%
isoflurane, intubated, and ventilated. Body temperature was
maintained at 37°C. The chest was then opened and the apex
of the left ventricle exposed. A 25-gauge needle was used to
make a stab wound near the apex of the heart and the
catheter was inserted. Baseline PV loops were recorded as
well as vena cava inferior occlusions.24
RNA Isolation and Quantitative PCR
Total RNA was isolated from mouse left ventricles using the
Qiagen AllPrep Kit (Qiagen, Valencia, CA) following the
manufacturer’s protocol. First-strand cDNA was transcribed
using random primers and SuperScript II Reverse Transcrip-
tase (Invitrogen). Real-time quantitative PCR was performed
using ABsolute SYBR Green ROX mix (Thermo Scientific).
Primers used are found in Table 1.
Preparation of Lysates and Immunoblot Analysis
Hearts were homogenized and protein was extracted in a RIPA
lysis buffer (50 mmol/L HEPES, 150 mmol/L NaCl, 2 mmol/
L EDTA, 0.5% Triton X-100, 0.5% Na-Deoxycholate, 1% NP-40,
25 mmol/L b-glycerophosphate, 10% glycerol, 1 mmol/L
sodium orthovanadate, 1 mmol/L phenylsulphfonyl fluoride,
10 lg/mL leupeptin, 10 lg/mL aprotinin, 10 mmol/L
sodium fluoride, 1 mmol/L sodium pyrophosphate, pH 7.2).
Protein extracts (30 lg) were subjected to Western blot
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analysis with antibodies against pTyr877ErbB2, pTyr1284-
ErbB4 (Cell Signaling); GAPDH (Millipore, Co, Bedford, MA).
Vinculin was from Sigma. Immunocomplexes were detected
using the Licor Odyssey secondary detection system. NRG-1b
antibody was a gift from D. Sawyer. Media was concentrated
as previously described25 using Amicon Ultra-15 with Ultracel-
3 membrane (Millipore, Co, Bedford, MA).
Histological Analysis and Immunohistochemistry
Hearts were perfused with 4% paraformaldehyde for 24 hours
and then switched to 70% ethanol. The hearts were then paraffin
embedded and sectioned into 5 lm sections and stained with
hematoxylin and eosin to assess overall morphology.21 For
cross-sectional analysis of cardiomyocytes and determination
of capillary density, heart sections were stained with TRITC
(tetramethylrhodamine)-conjugated lectin (Triticum vulgaris)
and examined by fluorescence microscopy as previously
described.21,22
Cardiomyocyte Isolation/Functional Assays
Adult mouse cardiomyocyte isolation, experimentation, and
analysis from PECAM-1+/+ and PECAM-1/ mice were
performed as previously described.26,27
Intracellular Calcium Measurements
Myocytes were loaded with 5 to 10 lmol/L Fluo-4 AM
(Molecular Probes) and placed in a heated chamber (35°C) on
the stage of an inverted microscope and perfused with
physiological Tyrode’s solution containing 150 mmol/L NaCl,
5.4 mmol/L KCl, 1.2 mmol/L MgCl2, 10 mmol/L glucose,
2 mmol/L Na-pyruvate, 1 mmol/L CaCl2, and 5 mmol/l
HEPES, pH 7.4. Myocytes were paced at 0.5 Hz and fractional
shortening data was collected using edge detection. For
[Ca2+]i fluorescence measurements, the F0 (or F unstimu-
lated) was measured as the average fluorescence of the cell
50 ms prior to stimulation. The maximal Fluo-4 fluorescence
(F) was measured at peak amplitude. Isoproterenol (Sigma)
was used at 1 lmol/L.
Blood Pressure Measurements
Blood pressure was measured non-invasively by a volume
pressure-recording sensor and an occlusion tail-cuff (CODA
System; Kent Scientific, Torrington, CT).
Tissue Hypoxia Staining
Tissue hypoxia was assessed using the HypoxyprobeTM-1 Kit
(Hypoxyprobe, Inc, Burlington, MA) according to the
manufacturer’s instructions. Briefly, animals were injected
i.p. with 60 mg/kg hypoxyprobe for 60 minutes. Hearts
were then harvested and fixed in 4% PFA, embedded in
paraffin and sectioned at 8 lm. Tissue sections were
stained with the Hypoxyprobe-1 antibody and visualized
using DAB.
Transmission Electron Microscopy
For electron microscopy, animals were euthanized and
perfused with freshly made fixative containing 2% parafor-
maldehyde and 2.5% glutaraldehyde in 0.15 mol/L sodium
phosphate buffer, pH 7.4. After perfusion, the hearts were
removed and cut into 1 to 2 mm3 cubes and stored from
several hours to overnight in the fixative before processing
for electron microscopy. Sections were observed using a
LEO EM910 transmission electron microscope operating at
80 kV (Carl Zeiss SMT, Inc, Peabody, MA) and photo-
graphed using a Gatan Orius SC1000 Digital Camera and
Digital Micrograph 3.11.0 (Gatan, Inc, Pleasanton, CA).
ROS Assays
Confluent endothelial cells were preincubated with 10 lmol/
L of 2,7-dichlorodihydrofluoroscein diacetate (H2-DCFDA)
at 37°C for 30 minutes. Cells were rinsed with PBS and




















bMHC indicates myosin heavy chain; ANP, atrial natriuretic peptide; PCR, polymerase
chain reaction; PECAM, platelet endothelial cell adhesion molecule.
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lysed in PBS containing 0.2% Triton X-100 and 1 mmol/L
N-acetylcystein. Fluorescence was measured using the
485 nm excitation/535 nm emission filter in a Wallac Victor
1420 MULTILABEL plate reader and normalized to total
protein concentrations in the lysates which were determined
using Bradford assay (Pierce).
Conditioned Media and Blocking Antibody Assays
A blocking antibody against human NRG-1 was purchased
from R&D Systems (Minneapolis, MN). Endothelial media
(0.1% FBS) was conditioned for 48 hours from a confluent
monolayer. Thirty minutes prior to treatment of the HL-1
cells, 25 lg/mL of blocking antibody was added and
incubated at 37°C. Cells were treated with the conditioned
media for 15 minutes and then homogenized in RIPA lysis
buffer. Protein extracts were subjected to Western blot
analysis.28
Inhibition of NRG-1 In Vivo
Twelve-week old male PECAM/ mice were treated with
either saline or 4 lg of NRG-1 EGF-domain blocking antibody
(R&D Systems) via intraperitoneal injections. Echos were
performed at baseline and 24 hours post-injection.
Quantitation and Statistical Analysis
The band intensity was quantitated using ImageJ software.
Each experimental group was analyzed using single factor
analysis of variance (Excel; Microsoft). Probability values
were obtained by performing a 2-tailed Student’s t test using
the same program. Mann-Whitney tests were also used
(GraphPad Prism). Statistical significance was defined as
P<0.05.
Results
PECAM-1/ Mice Exhibit Both Systolic and
Diastolic Dysfunction Indicative of Dilated
Cardiomyopathy
To assess cardiac performance of PECAM-1/ animals, we
performed transthoracic echocardiography in conscious 14-
to 16-week-old male mice (Figure 1, Table 2). We observed a
significant enlargement of the left ventricular (LV) chamber at
end diastole (LVID;d) in PECAM-1/ mice compared to
PECAM-1+/+ mice (Figure 1A and 1B). Echocardiography also
revealed impairment of LV function in PECAM-1/ hearts, as
evidenced by decreased ejection fraction and fractional
shortening (Figure 1C). Interestingly, there was no significant
difference in wall thickness at end diastole (Table 2). We did,
however, observe an increase in left ventricular mass
(Figure 1D). This phenotype was present at every post-natal
time point evaluated (Figure 1E and 1F; Table 3). In summary,
the echocardiographic data suggest that PECAM-1/ mice
have LV chamber dilation and systolic dysfunction, suggestive
of dilated cardiomyopathy (DCM).
Cardiac function was further evaluated in anesthetized
mice by in vivo cardiac catheterization. Representative images
from PECAM-1+/+ (black trace) and PECAM-1/ (red trace)
pressure-volume (PV) loops are shown (Figure 2A). PECAM-
1/ mice displayed increased end-systolic (ESV) and end-
diastolic (EDV) volumes (Table 4). Conversely, there was a
decrease in end-systolic pressure (ESP) (Table 4). These data
are in agreement with observations made by echocardiogra-
phy, further suggesting dilated cardiomyopathy in the PECAM-
1/ mice. Interestingly, the PV loop data also revealed a
significant decrease in both the maximum and minimum
derivatives of pressure development (+dP/dt and dP/dt),
indicating impaired rates of contraction and relaxation, respec-
tively, in the PECAM-1/ mice (Figure 2B). Importantly, we
do not see an increase in diastolic pressures, suggest-
ing that the PECAM-1/ mice have compensated heart
failure.
Reactivation of the fetal gene program is a common
marker for various cardiac pathologies, including hypertro-
phy and DCM.29 We therefore assessed fetal gene expres-
sion in adult PECAM-1+/+ and PECAM-1/ hearts by
quantitative PCR. The expression of b-myosin heavy chain
(bMHC), atrial natriuretic peptide (ANP) and a-skeletal
actin (aSka) were significantly increased in PECAM-1/
hearts compared with PECAM-1+/+ littermates (Figure 3A).
These data support our echocardiographic data and
further indicate that genetic deletion of PECAM-1 results
in DCM.
Studies indicate that increased blood pressure (hyperten-
sion) can lead to heart failure.30,31 To exclude the possibility
that differences in blood pressure account for the impaired
cardiac function in the PECAM-1/ mouse, we measured
mean arterial pressures (MAP) in conscious 12- to 14-week-
old mice. There was no significant difference in pressures
between genotypes (Figure 3B), suggesting that cardiac
dysfunction in the PECAM-1/ animals is not associated
with or a direct result of hypertension.
Normal Vascular and Cardiomyocyte Architecture
in PECAM-1/ Hearts
Recent studies have suggested a role for defective vascu-
larization in the pathogenesis of DCM.3 Because PECAM-1 is
expressed in ECs, and ECs line blood vessel walls, we
hypothesized that differences in cardiac vascularity might
account for differences in cardiac function of PECAM-1/
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animals. There were no obvious defects in coronary artery
structure or number in PECAM-1/ hearts (data not
shown) and no indication of hypoxia in PECAM-1/ heart
tissue (Figure 4). Measurements of capillary density by
TRITC-lectin staining revealed a small increase in PECAM-
1/ hearts (Figures 5A and 5B), suggesting that cardiac
defects are not attributable to differences in capillary
density.
The fundamental contractile unit of cardiac muscle is the
sarcomere. Previous studies have shown that defects in
sarcomere protein expression and structure can lead to
DCM.32 In order to determine if alterations in sarcomere
structure could explain the impaired contractility of PECAM-
1/ hearts, we performed transmission electron microscopy
(TEM). We did not detect any differences in sarcomere
organization or size between PECAM-1+/+ and PECAM-1/
mice (Figure 5C). When taken together, our studies suggest
that the impaired cardiac function in PECAM-1/ animals is
not associated with structural or architectural defects in the
heart and raise the possibility that impaired cardiac function





Figure 1. PECAM-1/ mice have increased chamber size with systolic and diastolic dysfunction. A, Representative image of M-Mode
echocardiography for baseline heart function in age-matched adult PECAM-1+/+ and PECAM-1/ mice. B and C, Echocardiographic
measurement assessment of left ventricular dilation and cardiac function. Echocardiography data represent at least 10 mice per group
(*P<0.01). Measurements were collected at the level of the papillary muscle. D, Analysis of left ventricle weight to tibia length to normalize left
ventricular mass (n=10/genotype, *P<0.005). E and F, Echocardiographic measurement assessment of left ventricular function by fractional
shortening (E) and ejection fraction (F). Echocardiography data represent 10 mice per group (*P<0.01). LVID indicates left ventricular internal
dimension; PECAM-1, platelet endothelial cell adhesion molecule.
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Cardiomyocytes Isolated From PECAM-1/
Hearts Display Normal Contractility
EC-cardiomyocyte communication is thought to play an
important role in regulating cardiac function, as ECs not
only provide a lifeline for cardiomyocyte survival but they
also can regulate cardiomyocyte signaling and function via
secretion of growth factors, cytokines and other signaling
molecules.2 PECAM-1 has previously been reported to be
absent from cardiomyocytes,33,34 and our own data verified
that PECAM-1 is not expressed in cardiomyocytes (Fig-
ure 6). We therefore hypothesized that absence of PECAM-
1 in ECs leads to impaired EC-cardiomyocyte communica-
tion. Accordingly, we hypothesized that cardiomyocytes
isolated from PECAM-1/ hearts (and not under the
influence of ECs) are indistinguishable from those isolated
from PECAM-1+/+ hearts. To test this, we isolated cardio-
myocytes from PECAM-1+/+ and PECAM-1/ hearts and
measured baseline contraction. As shown in Figures 7A and
7C, cardiomyocytes isolated from PECAM-1+/+ and PECAM-
Table 2. Echocardiographic Data From PECAM-1+/+ and PECAM-1/ Mice
PECAM-1+/+ (n=9) PECAM-1/ (n=10)
Heart rate (BPM) 71016 66013*
IVS;d (mm) 1.00.02 1.1 0.02
IVS;s (mm) 1.70.02 1.6 0.02
LVPW;d (mm) 0.960.01 0.990.02
LVPW;s (mm) 1.520.02 1.40.03
LVID;d (mm) 2.90.2 3.30.1*
LVID;s (mm) 1.40.1 2.060.08
LV Vol;d (lL) 34.95.1 44.63.9
LV Vol;s (lL) 5.31.0 14.21.4
EF% 85.50.9 68.21.1†
FS% 48.32.4 37.20.9†
The values presented represent the meanSE. EF indicates ejection fraction; FS, fractional shortening; HR, heart rate; IVS, interventricular septum; LV vol, left ventricular volume; LVID, left
ventricular internal dimension; LVPW, left ventricular posterior wall; PECAM, platelet endothelial cell adhesion molecule.
*P<0.005 PECAM-1/ vs PECAM-1+/+.
†P<0.01 PECAM-1/ vs PECAM-1+/+.
Table 3. Aging Echocardiographic Data From PECAM-1+/+ and PECAM-1/ Mice
PECAM-1+/+ (n=9) PECAM-1/ (n=10)
4 weeks 8 weeks 12 weeks 4 weeks 8 weeks 12 weeks
Heart Rate (BPM) 68424 7378 7259 61224 66422 67817
IVS;d (mm) 0.730.01 0.880.03 0.980.03 0.700.03 0.860.02 0.990.02
IVS;s (mm) 1.20.03 1.460.03 1.620.02 1.070.05* 1.350.04* 1.570.04
LVPW;d (mm) 0.70.02 0.80.03 0.910.03 0.620.03† 0.820.04 0.920.04
LVPW;s (mm) 1.150.04 1.330.04 1.490.05 0.930.02† 1.20.06 1.340.05
LVID;d (mm) 2.40.1 2.70.07 2.90.05 2.80.1* 3.30.2† 3.20.13*
LVID;s (mm) 1.360.08 1.50.05 1.530.06 1.890.09† 2.20.2† 2.10.1†
LV Vol;d (lL) 21.31.87 27.11.68 31.21.25 29.52.8* 46.86.0† 42.54.1*
LV Vol;s (lL) 4.90.6 6.170.5 6.520.63 11.41.4† 14.93.2† 14.72.5‡
EF% 76.92.2 77.31.0 79.81.5 61.62.1† 64.92.5† 65.22.4†
FS% 44.12.0 44.30.9 47.21.5 31.91.5† 34.71.7 34.91.8†
The values presented represent the meanSE. EF indicates ejection fraction; FS, fractional shortening; HR, heart rate; IVS, interventricular septum; LV vol, left ventricular volume; LVID, left
ventricular internal dimension; LVPW, left ventricular posterior wall.
*P<0.05, †P<0.005, ‡P<0.01. All statistics were calculated PECAM-1/ vs PECAM-1+/+ at corresponding age.
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1/ hearts had identical baseline contraction. Further-
more, no differences were observed in either peak systolic
[Ca2+]i transients (Figures 7B and 7D) or the rate of [Ca
2+]i
transient decay (Figures 7B and 7E). Similarly, no differ-
ences were observed in the average resting length of
cardiomyocytes from either genotype (data not shown).
Finally, cardiomyocytes isolated from PECAM-1+/+ and
PECAM-1/ hearts responded similarly to the b-adrenergic
agonist isoproterenol. These findings show that cardiomyo-
cytes isolated from PECAM-1/ or PECAM-1+/+ hearts are
indistinguishable in their ability to contract (baseline and in
response to isoproterenol) in the absence of EC input;
these data provide support for the notion that an
endothelial-derived signal may be responsible for the
cardiac dysfunction in the PECAM-1/ mouse.
Misregulated Neuregulin-ErbB Signaling in the
PECAM-1/ Mice
To further test the hypothesis that EC-cardiomyocyte com-
munication is altered in PECAM-1/ mice, we examined the
involvement of known mediators of paracrine signaling. Of
particular interest is the endothelial-derived signaling mole-
cule NRG-1. This EGF-family protein is cleaved at the EC
membrane, which releases the active, EGF-domain-containing
peptide that is capable of binding to ErbB receptors expressed
Table 4. Hemodynamic Measurements From PECAM-1+/+ and PECAM-1/ Mice
PECAM-1+/+ (n=8) PECAM-1/ (n=8)
HR, BPM 5527 5046*
ESP, mm Hg 75.52.3 62.42.1†
EDP, mm Hg 4.30.3 4.10.4
ESV, lL 17.82.6 26.02.0*
EDV, lL 39.82.4 47.41.7*
EF, % 57.54.5 45.62.4†
ESPVR slope 7.20.8 6.71.0
ESPVR intercept 0.64.2 13.51.8*
PRSW intercept 16.62.4 28.42.4†
PVA vs EDV intercept 17.02.7 27.12.4*
The values presented represent the meanSE. EDP indicates end-diastolic pressure; EDV, end-diastolic volume; EF, ejection fraction; ESP, end-systolic pressure; ESPVR, end-systolic
pressure-volume relationship; ESV, end-systolic volume; HR, heart rate; PRSW, preload recruitable stroke work; PVA, pressure-volume area.
*P<0.005 PECAM-1/ vs PECAM-1+/+.
†P<0.01 PECAM-1/ vs PECAM-1+/+.
A B
Figure 2. Decreased contractility and relaxation in PECAM-1/ hearts. A, Representative left ventricular (LV) pressure-volume (PV) loops
during preload reduction (vena cava occlusion) in PECAM-1+/+ (black trace) and PECAM-1/ mice (red trace). B, Maximum and minimum rates
of pressure change in the left ventricle (n=8/genotype, *P<0.005). PECAM-1 indicates platelet endothelial cell adhesion molecule.
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on cardiomyocytes. Within cardiomyocytes, ErbB receptors
initiate signal transduction pathways that ultimately regulate
cardiomyocyte contractility.28,35
To determine if the NRG-ErbB pathway is altered in the
absence of PECAM-1, NRG-1 release from ECs was
assessed. We measured the cleaved fragment of NRG-1
present in conditioned cell media from PECAM-1 knockout
(PE-KO) and PECAM-1 expressing (PE-RC) ECs by immuno-
blot analysis. We observed a small but significant increase in
NRG-1 in the conditioned media of PE-KO cells compared to
PE-RC cells (Figure 8A). To verify that increased NRG-1 also
occurs in vivo, heart lysates from PECAM-1+/+ and PECAM-
1/ animals were assessed for NRG-1 levels. Similar to our
observations in vitro, we found higher levels of NRG-1 in
PECAM-1/ hearts (Figure 8B). In further support for the
elevated NRG-1 in PECAM-1/ hearts in vivo, we observed
a tendency for increased cardiomyocyte area in the PECAM-
1/ hearts (Figure 5B), consistent with previous studies
showing that NRG-1 promotes hypertrophy.36 Additionally,
we observed increased reactive oxygen species (ROS)
production in PECAM-1 KO ECs, consistent with the
observation that NRG-1 release is mediated by ROS37 and
the finding that coronary arteries from PECAM-1/ mice
have increased ROS production16 (Figure 8C). To provide
additional mechanistic insight into the regulation of NRG-1
release from the PE-KO cells, we treated both PE-RC and PE-
KO cell either with diphenyleneiodonium (DPI), a ROS
inhibitor, or L-NG-nitroarginine methyl ester (L-NAME), an
NO inhibitor. We found that blockage of either ROS or NO
significantly reduced NRG-1 levels in media from the PE-KO
Figure 4. No evidence for hypoxia in PECAM-1/ hearts. PECAM-1+/+ and PECAM-1/ were injected
with Hypoxyprobe-1TM prior to sacrifice. The tissue was fixed, paraffin-embedded and sectioned. There was
no apparent positive staining in either genotype. PECAM-1 indicates platelet endothelial cell adhesion
molecule.
A B
Figure 3. Characterization of PECAM-1/ gene expression and blood pressure. A, Quantitative real-time
RT-PCR of cardiac fetal gene expression in 12-week-old male mice. All mRNA species were quantified
relative to 18s housekeeping gene expression and presented as fold change (arbitrary units [AU]) relative to
PECAM-1+/+ mice. (n=3/genotype, *P<0.01 #P<0.05). B, Blood pressures from PECAM-1+/+ and PECAM-
1/ mice were performed by tail-cuff measurement (n=10/genotype). aMHC indicates a myosin heavy
chain; aSka, a skeletal actin; bMHC, b-myosin heavy chain; ANP, atrial natriuretic peptide.
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cells (Figure 8D). These data suggest that elevated NO/ROS
signaling from PE-KO cells contribute to the elevated NRG-1
signaling in PECAM-1/ animals.
Binding of NRG-1 induces rapid tyrosine phosphorylation
of the ErbB receptor expressed in cardiomyocytes. We
therefore evaluated if the increased NRG-1 observed in
PECAM-1/ hearts results in elevated phosphorylation of
its receptor in vivo. Importantly, we observed enhanced
ErbB2 tyrosine phosphorylation in PECAM-1/ hearts
(Figure 8E), suggesting that the misregulated NRG-1 release
leads to hyperactivation of ErbB receptor signaling. We
extended these studies further by developing an in vitro
system to test the hypothesis that increased NRG-1 release
from PECAM-1/ ECs is responsible for hyperactivation of
the ErbB receptor in cardiomyocytes. We incubated mouse
cardiomyocytes with conditioned media from PE-KO or PE-
RC cells and compared ErbB2 phosphorylation levels. As
shown in Figure 9A, incubation of cardiomyocytes with
conditioned media from PE-KO ECs resulted in a significant
increase in pTyr877ErbB2 levels compared to when cardio-
myocytes were incubated with conditioned media from PE-
RC ECs (3.7-fold versus 10.9-fold). Importantly, pre-incuba-
tion of PE-KO conditioned media with an NRG-1 blocking
antibody significantly reduced ErbB2 phosphorylation levels




Figure 5. PECAM-1/ hearts have normal tissue and ultrastructural architecture. A, TRITC (tetramethylrhodamine)-lectin stained sections for
baseline cardiomyocyte cross-sectional area and capillary density in PECAM-1+/+ and PECAM-1/ mice. Scale bar 20 lm. B, Quantitation of
images shown in (A), (n=4 PECAM-1+/+ and n=3 PECAM-1/, *P<0.01). C, The ultrastructure of cardiac muscle from PECAM-1+/+ and PECAM-
1/ mice by transmission electron micrograph. 910000 and 925000 representative images shown, scale bars 2 and 1 lm, respectively.
PECAM-1 indicates platelet endothelial cell adhesion molecule.
Figure 6. Adult mouse cardiomyocytes do not
express PECAM-1. qPCR was performed on RNA
isolated from 2 lines of mouse endothelial cells as
well as mouse cardiomyocytes (HL1) cells. No
expression was detected in the cardiomyocytes
(CMs) compared to the robust signal from the
endothelial cells. PECAM-1 indicates platelet endo-
thelial cell adhesion molecule.
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in cardiomyocytes treated with conditioned media from
PECAM-1-expressing ECs. These data provide further cre-
dence to the misregulated NRG-1/ErbB2 pathway in
PECAM-1/ hearts.
NRG-1 Blockade Restores Cardiac Function in
PECAM-1/ Mice
Our results so far have revealed that absence of PECAM-1
is associated with increased NRG-1 release and increased
ErbB2 phosphorylation; we have also shown that the
increased NRG-1 released from PECAM-1 KO ECs is
responsible for the increased ErbB2 phosphorylation, as
treatment of isolated cardiomyocytes with conditioned
media from PECAM-1 KO ECs results in enhanced ErbB2
phosphorylation that can be normalized by an NRG-1
blocking antibody. We hypothesized that aberrant NRG-1
signaling in ECs contributes to the cardiac dysfunction of
PECAM-1/ mice, and if this notion was correct, we
posited that NRG-1 blocking antibody administration might
be cardioprotective. Age-matched, adult PECAM-1/ mice
were treated with the NRG-1 blocking antibody or saline
(Figures 9C and 9D; Table 5). Conscious echocardiography
revealed that PECAM-1/ mice demonstrated a significant
improvement in left ventricular ejection fraction and
fractional shortening after NRG-1 blocking antibody treat-
ment, compared to saline control-treated PECAM-1/ mice
(fractional shortening: 40.9% versus 33.0%; ejection frac-
tion: 72.8% versus 62.4%). These data show that the excess
NRG-1 levels observed in PECAM-1/ ECs and hearts and
the ensuing elevated ErbB activation, play a key causative
role in the impaired cardiac function observed in the
PECAM-1/ mice.
Discussion
The findings presented here support a model in which PECAM-
1 modulates cardiac contractility via a paracrine mechanism
that involves the NRG-1/ErbB2 pathway. Although PECAM-
1/ animals display impaired cardiac function, surprisingly,
cardiomyocytes isolated from these mice show normal




Figure 7. Cardiomyocytes isolated from PECAM-1/ hearts have preserved contractility and calcium transients. A and B, Representative
examples of contractions (A) and calcium transients (B) from cardiomyocytes isolated from PECAM-1+/+ or PECAM-1/ mice at baseline and
after isoproterenol treatment. C through E, Average data measuring fractional shortening (C), peak calcium transients (D), and calcium decay
rate (E) in isolated cardiomyocytes from PECAM-1+/+ and PECAM-1/ miceisoproterenol. PECAM-1 indicates platelet endothelial cell
adhesion molecule.
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the reduced contractility observed in vivo is due to an
endothelial-derived signal, as cardiomyocytes from PECAM-
1/ mice exhibit impaired contractility only when under the
influence of ECs. Our data indicated that the absence of
PECAM-1 results in elevated NO/ROS signaling and enhanced
NRG-1 release from ECs that, in turn, leads to aberrant
activation of the ErbB2 receptor in cardiomyocytes. In support
of this model, treatment of PECAM-1/ mice with NRG-1
EGF-domain blocking antibody resulted in improved cardiac
function, as evidenced by increased left ventricular fractional
shortening and ejection fraction. Overall, these results provide
support for the model that precise spatiotemporal activation
of the NRG-1/ErbB signaling cascade is crucial for normal
cardiac function and that absence of PECAM-1 from ECs
results in augmented NRG-1 release and impaired cardiomyo-
cyte contractility which can be acutely reversed by an NRG-1-
blocking antibody.
The rather intuitive consensus in the field is that EC
signaling can affect global cardiac function. However, studies
supporting this dogma are limited. There are only a handful of
reports of EC-specific knockout animals demonstrating
impaired cardiac contractility. Importantly, not all EC knock-
out models display a basal cardiac phenotype. For example,




Figure 8. Misregulated NRG-1/ErbB signaling in PECAM-1/ hearts. A, Quantitation of Western blot for
NRG-1b release from PE-RC and PE-KO cells. Media was collected after 24 hours and concentrated.
Concentrated media was then run on a polyacrylamide gel (n=5, *P<0.05). B, Quantitation of Western blot
for NRG-1b in heart tissue from PECAM-1+/+ and PECAM-1/ hearts. (P<0.05). C, Measurement of
reactive oxygen species (ROS) production from PE-RC and PE-KO cells using 2,7-H2DCFDA. Fluorescence
was measured using a plate reader and normalized to total protein levels in the lysate (n=7, *P<0.01). D,
Quantification of Western blots for NRG-1b from PE-RC and PE-KO cells treated with either DPI or L-NAME
for 24 hours (n=3, *P<0.05). E, Representative Western blots for pTyr877ErbB2 (n=6/genotype). DCFDA
indicates 2,7-dichlorodihydrofluoroscein diacetate; DPI, diphenyleneiodonium; NRG-1, neuregulin.
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Figure 9. NRG-1 blockade normalizes ErbB2 phosphorylation and restores cardiac function in PECAM-1/ mice. A, Western blot and
quantitation of pTyr877ErbB2 in HL-1 cardiomyocytes treated with either unconditioned media or EC-conditioned media from PE-RC, PE-KO or
PE-KO plus 25 lg/mL NRG-1 blocking antibody. B, Representative image of M-Mode echocardiography for heart function in adult PECAM-1/
mice treated with vehicle or NRG-1 blocking antibody. C to D, Echocardiographic measurement assessment of left ventricular ejection fraction
and fractional shortening. Echocardiography results (D) represent 10 mice per group (*P<0.05, #P<0.001). Measurements were collected at the
level of the papillary muscle. EC indicates endothelial cells; NRG-1, neuregulin; PECAM-1 indicates platelet endothelial cell adhesion molecule.
Table 5. Echocardiographic Data From NRG-1 Blocking Antibody
Saline (n=10) aNRG-1 (n=10)
Baseline Saline Baseline Blocking Ab
Heart rate, BPM 60331 63531 64934 68920
IVS;d (mm) 0.940.02 0.970.02 0.930.02 0.960.03
IVS;s (mm) 1.40.02 1.50.05 1.40.03 1.60.4*
LVPW;d (mm) 0.850.03 0.800.03 0.780.04 0.780.03
LVPW;s (mm) 1.250.03 1.200.06 1.220.07 1.280.04
LVID;d (mm) 2.950.13 3.280.15 3.330.16 3.090.09
LVID;s (mm) 1.980.11 2.200.13 2.200.14 1.830.08†,‡
LV Vol;d (lL) 34.63.9 44.95.5 46.55.2 38.42.8
LV Vol;s (lL) 13.12.0 17.43.0 17.22.5 10.51.1†,‡
EF% 62.72.6 62.42.7 63.62.9 72.82.1†,‡
FS% 32.91.9 33.01.9 34.12.3 40.91.7†,§
The values presented represent the meanSE. EF indicates ejection fraction; FS, fractional shortening; HR, heart rate; IVS, interventricular septum; LV vol, left ventricular volume; LVID, left
ventricular internal dimension; LVPW, left ventricular posterior wall; NRG-1, neuregulin.
*P<0.01 baseline vs blocking Ab.
†P<0.05 baseline vs blocking Ab.
‡P<0.05 blocking Ab vs saline.
§P<0.001 blocking Ab vs saline.
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once challenged, there is rapid decompensation to heart
failure.38 Previously, work in the caveolin-1 global knockout
mouse showed development of DCM at 5 months of age39;
this was attributed to misregulation of eNOS/NO signaling in
non-myocytes. Although it is accepted that ECs release
molecules that can affect cardiomyocyte function, the mech-
anisms that regulate this release remain unclear. Our study
places PECAM-1 as a central player in NRG-1-dependent
intercellular communication between the endocardium and
myocardium, which is crucial in controlling cardiac contrac-
tility and function.
Although we cannot exclude the possibility that other
PECAM-1-expressing cells, such as leukocytes, may contrib-
ute to the impaired cardiac function of the PECAM-1/ mice,
the deletion of PECAM-1 in ECs is the likely culprit based on
the observation of increased NRG-1 release from PECAM-1/
 ECs. In addition, several other pieces of data argue against
a role for hematopoietic PECAM-1. First, previous studies
have shown no difference in either leukocyte or platelet
counts in PECAM-1/ mice.40 Second, on a C57Bl/6
background, no differences in platelet activation41 or leuko-
cyte emigration have been observed in PECAM-1/ ani-
mals.40 Furthermore, the contribution of leukocytes to the
total cell population of a normal heart is minimal compared
with that from either fibroblasts or endothelial cells.42 Finally,
each cardiomyocyte is in close physical contact with the
surrounding EC-derived vasculature facilitating a unique
interface for cellular crosstalk. Thus, we propose that
endothelial PECAM-1 is essential for regulating cardiac
function.
The effects of NRG-1 signaling in the cardiovascular
system are strongly time- and tissue-dependent,43 and NRG-
1 has been reported to have both positive and negative
effects on cardiac contractile function. Knockout models have
indicated a requirement for NRG-1 in directing morphogenesis
of the developing ventricles (trabeculation), as well as
differentiation of cardiac stem cells. Within the adult heart,
NRG-1 is important for paracrine signaling between ECs and
cardiomyocytes to maintain adaptation of the heart to
physiological and pathological stimuli. In support of this idea,
administration of recombinant NRG-1 during acute cardiac
injury and during chronic heart failure has beneficial effects
on both survival and restoration of cardiac function.9,44,45
These observations have been expanded into human models
showing similar benefits to administration of NRG-1.45,46 It is
important to point out that the beneficial effects of NRG-1
have been observed in settings of induced heart failure; this is
discordant with our model where no heart failure has been
induced.
Despite ongoing studies on development of recombinant
NRG-1 as a possible therapy for heart failure, our under-
standing of the NRG/ErbB signaling axis is still underdevel-
oped. NRG-1 is activated in the heart after injury37 and by
changes in hemodynamic load.47 Interestingly, NRG-1 levels
are higher in patients with stress-induced ischemia and higher
serum NRG-1 levels are associated with poor prognosis in
patients with chronic heart failure.48 The elevated serum NRG-
1 levels in heart failure could either be viewed as a favorable
compensatory response or as pathogenic,48 although more
studies are needed to distinguish between these 2 possibil-
ities. In addition, and perhaps antithetically to its cardiopro-
tective effects, NRG-1 induces a negative inotropic response
in adult cardiac muscle, at least in part, via nitric oxide
(NO).43,49 Interestingly, we,14,17 and others,50 have previously
reported enhanced eNOS activation and NO production in
PECAM-1/ animals, although the role of NO in regulating
cardiac contractility is somewhat conflicting.51 The negative
inotropic effects of NRG-1 suggest that the elevated NRG-1
signaling in the absence of PECAM-1 may be responsible for
the observed depressed cardiac contractility in PECAM-1 /
animals. Consistent with this hypothesis, administration of a
blocking antibody against NRG-1 protected PECAM-1/
animals and restored cardiac function to levels comparable to
those observed in WT animals. Our observations allow us to
surmise that precise fine-tuning of the NRG-1/ErbB pathway
is crucial for maintenance of proper cardiac function.
This research furthers our understanding of the effects of
PECAM-1 in various aspects of cardiovascular biology. It is
unclear exactly how PECAM-1 directs NRG-1 cleavage and
signaling. Future studies are aimed at understanding this
relationship. Our data implicate a role for ROS production in
this regulation but other aspects of PECAM-1 biology should
be considered. For example, changes in hemodynamic forces
in the heart have been implicated in cardiac dysfunction. Work
from our lab and others have highlighted PECAM-1 as a
critical endothelial mechanosensor. Thus, PECAM-1-depen-
dent mechanosignaling may also influence cardiac function.
Nevertheless, while it is possible that other aspects of
PECAM-1 function may contribute to the observed cardiac
phenotype in PECAM-1/ mice, the work presented here
clearly identifies PECAM-1 as a novel regulator of EC-
cardiomyocyte crosstalk.
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